I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
Rivista di Chirurgia
Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index
Chirurgia 2016 Dicembre;29(6):195-9
Zero ischemia laparoscopic minimal invasive partial nephrectomy “modified sequential preplaced suture renorrhaphy technique”
Mehmet G. SÖNMEZ, Cengiz KARA
Medical Park Ankara Hospital, Department of Urology, Ankara, Turkey
BACKGROUND: In T1 phase renal cancers, minimal invasive partial nephrectomy (MIPN) should be preferred. In this article we wanted to share our experiences on zero ischemia laparoscopic minimal invasive partial nephrectomy done with Modified Sequential preplaced suture renorrhaphy technique.
METHODS: The mass in a total of ten renal units in 9 patients in whom kidney tumors were determined incidentally and didn’t cause any complaints were extracted with laparoscopic partial nephrectomy using ‘’Modified sequential preplaced suture renorrhaphy technique’’. These masses were evaluated with R.E.N.A.L nephrometry and PADUA score system. During selection, exophytic tumors with a dimension of ≤ 4 cm and which don’t have a relationship with collecting system were preferred.
RESULTS: Average age of the patients was measured as 62.8 years (49-72). Out of 9 patients, 6 were male and 3 were female. Average R.E.N.A.L. score was 5.7, PADUA score was 6.8 and average tumor diameter was 2,8 cm. Average operation duration was 136 minutes, hospitalization period was 54.2 hours, bleeding amount was 205 mL. Clavien-Dindo class 1-2 complication was observed in two patients in total (22.2%). Clavien-Dindo class 3-4 complication was not observed in any of the patients. Patients were followed for 11.7 months in average.
CONCLUSIONS: Modified Sequential preplaced suture renorrhaphy technique is an effective and thrusted method in the preservation of renal functions and nephrons. This method removes the damage caused by warm ischemia on the kidney. But due to limitations, it can be applied in limited patients who have kidney tumors.